We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 36

Paying Royalties for Technology that Competitors Can Use for Free - AG Wathelet’s Genentech Opinion
  • McDermott Will & Emery
  • European Union
  • April 28 2016

The Court of Justice of the European Union (CJEU) recently issued its opinion on a question referred to it by the Paris Court of Appeal regarding the


What did you say? $31 million awarded for infringement of hearing aid patent
  • McDermott Will & Emery
  • European Union
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed


CJEU actavis and Eli Lilly SPC judgments
  • McDermott Will & Emery
  • European Union
  • January 22 2014

In addition to giving its decision in Georgetown University C-48412, the Court of Justice of the European Union (CJEU) handed down two other


Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates
  • McDermott Will & Emery
  • European Union
  • June 7 2012

Advocate General Trstenjak (the AG) has rendered an opinion in a preliminary reference relating to Neurim Pharmaceuticals Ltd 1991 C-13011 that it should be possible to grant a Supplementary Protection Certificate (SPC) for a second medicinal product that comprises the same active ingredient as a medicinal product covered by a prior marketing authorisation (MA), if the scope of the basic patent protecting the second medicinal product does not extend to the earlier medicinal product


SPCs: is a simplistic system becoming too complicated?
  • McDermott Will & Emery
  • European Union
  • November 22 2010

Obtaining and enforcing Supplementary Protection Certificates (SPCs) for medicinal products in the European Union is a fertile ground for challenge and the law is still unclear in a number of key areas


Navigating the evolving regulation and commercialization of stem cell research
  • McDermott Will & Emery
  • European Union, USA
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage


UK Supreme Court steps into line with Europe, but rejects U.S. approach
  • McDermott Will & Emery
  • European Union, United Kingdom, USA
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily


David Henry
  • McDermott Will & Emery

Lesley DeRenzo
  • McDermott Will & Emery

Lionel Lesur
  • McDermott Will & Emery